---
layout: default
title: Apraclonidine
parent: Model Prediction Only (L5)
nav_order: 394
evidence_level: L5
indication_count: 1
---

# Apraclonidine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Apraclonidine: From Ophthalmic Intraocular Pressure Control to Primary Hereditary Glaucoma

## One-Sentence Summary

Apraclonidine is a marketed ophthalmic solution, generally known for short-term control of intraocular pressure (IOP). The label indication text is not included in the supplied record.
The TxGNN model predicts it may be effective for **primary hereditary glaucoma**.
Currently **0 clinical trials** and **0 publications** support this direction, so this is a model-only prediction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in the supplied record (generally known for ophthalmic IOP control) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the record. Based on general pharmacology, apraclonidine is an alpha-2 adrenergic agonist that lowers IOP by reducing aqueous humor production. This is biologically plausible for glaucoma in general, but it has not been verified against the supplied record.

Glaucoma is fundamentally a disease of elevated or poorly controlled IOP, so an IOP-lowering drug is a reasonable candidate. The high score may simply reflect that apraclonidine is already an ocular drug rather than a true repurposing signal.

There is no evidence that it helps in hereditary forms (for example MYOC-related or congenital glaucoma). In those forms the disease mechanism and the need for long-term treatment differ. Tachyphylaxis and ocular allergy with long-term use are known limitations, and neither was assessed here.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| NDA020258 | Apraclonidine (Sandoz Inc) | Solution | Not specified in the record |
| NDA019779 | IOPIDINE 1% (Harrow Eye, LLC) | Solution/Drops | Not specified in the record |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction score is very high (99.88%), but there are no clinical trials or literature, and the mechanism and label indications are missing from the record. The signal may reflect the drug's existing ocular use rather than a new indication.

**To proceed, the following is needed:**
- Retrieve and parse the FDA package insert (label indications, warnings, contraindications), which is currently a blocking gap
- Confirm the mechanism of action and original indications from DrugBank or FDA records
- Search ClinicalTrials.gov and PubMed for hereditary, juvenile, or congenital glaucoma studies
- Assess whether short-term use, tachyphylaxis, and ocular allergy fit chronic hereditary glaucoma management
- Reassess the evidence level and decision once these are done
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

